NANOGEN INC Form 8-K October 27, 2008

## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

# FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2008

# NANOGEN, INC.

(Exact name of registrant specified in its charter)

Delaware (State or other jurisdiction of incorporation)

000-23541 (Commission File Number) 33-0489621 (I.R.S. Employer Identification No.)

10398 Pacific Center Court, San Diego, California (Address of principal executive offices) 92121 (Zip Code)

Registrant's telephone, including area code: (858) 410-4600

(Former name and former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

" Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01 Other Events

On October 16, 2008, NASDAQ Stock Market filed an immediately effective rule change to suspend enforcement of its \$1.00 minimum bid price requirement for listed companies through Friday, January 16, 2009. As previously disclosed in a Form 8-K filed by Nanogen, Inc. (the Company ) on May 23, 2008, the Company is not in compliance of the minimum bid price requirement and has until the end of November 2008 to regain compliance of such requirement. As a result of the rule change, on October 22, 2008 NASDAQ notified the Company that the Company will now have until February 26, 2009 to regain compliance of the minimum bid price requirement. The Company can regain compliance, either during the suspension or during the compliance period resuming after the suspension, by achieving a \$1.00 closing bid price for a minimum of 10 consecutive trading days.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## NANOGEN, INC.

Date: October 24, 2008 By: /s/ Nicholas Venuto

Name: Nicholas Venuto Title: Chief Financial Officer